- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07410117
REGN7508 til voksne deltakere for forebygging av kreft-assosiert trombose (ROXI-CAT-I)
En fase 3, multicenter, randomisert, dobbelblind, placebokontrollert studie for å vurdere effekt og sikkerhet av REGN7508, en monoklonal antistoff mot FXI, for primærprofilakse av kreft-assosiert trombose hos deltakere med solide tumorer som gjennomgår kreftbehandling (ROXI-CAT-I)
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-post: clinicaltrials@regeneron.com
Studiesteder
-
-
Florida
-
Hialeah, Florida, Forente stater, 33013
- Rekruttering
- Bioresearch Partner- Hialeah Hospital
-
North Miami Beach, Florida, Forente stater, 33169
- Rekruttering
- Helios Clinical Research
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Beth Israel Deaconess Medical Center
-
-
New York
-
New York, New York, Forente stater, 10021
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso, Texas, Forente stater, 79902
- Tilbaketrukket
- El Paso Medical Research Institute (Medresearch Inc)
-
-
-
-
-
Tbilisi, Georgia, 0159
- Rekruttering
- Institute of Clinical Oncology
-
Tbilisi, Georgia, 0186
- Rekruttering
- Caucasus Medical Centre
-
Tbilisi, Georgia, 0144
- Rekruttering
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Tbilisi, Georgia, 0179
- Rekruttering
- LTD Cancer Research Centre
-
Tbilisi, Georgia, 0179
- Rekruttering
- JSC Evex Hospitals - Caraps Medline
-
Tbilisi, Georgia, 0102
- Rekruttering
- American Hospital Tbilisi
-
Tbilisi, Georgia, 0112
- Rekruttering
- Llc Todua Clinic
-
Tbilisi, Georgia, 0112
- Rekruttering
- Israel Georgia Medical Research Clinic Helsicore
-
-
Adjara
-
Batumi, Adjara, Georgia, 6000
- Rekruttering
- LTD High Technology Hospital Medcenter
-
-
Imereti
-
Kutaisi, Imereti, Georgia, 4600
- Rekruttering
- Krystyna Kiel Oncology Center
-
-
-
-
-
Niigata, Japan, 951-8520
- Rekruttering
- Niigata University Medical & Dental Hospital
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Rekruttering
- Ehime University Hospital
-
-
Gunma
-
Ōta, Gunma, Japan, 373-8550
- Rekruttering
- Gunma Prefectural Cancer Center
-
-
Hyōgo
-
Akashi, Hyōgo, Japan, 673-8558
- Rekruttering
- Hyogo Cancer Center
-
-
Kagawa-ken
-
Kita-gun, Kagawa-ken, Japan, 761-0793
- Rekruttering
- Kagawa University Hospital
-
-
Kanagawa
-
Isehara-Shi, Kanagawa, Japan, 259-1193
- Rekruttering
- Tokai University Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 602-8566
- Rekruttering
- University Hospital Kyoto Prefectural University of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Rekruttering
- Tohoku University Hospital
-
-
Osaka
-
Chuo, Osaka, Japan, 540-0006
- Rekruttering
- National Hospital Organization Osaka National Hospital (ONH)
-
-
Saitama
-
Ina-machi, Saitama, Japan, 362-0806
- Rekruttering
- Saitama Cancer Center
-
-
Tokyo
-
Chuo Ku, Tokyo, Japan, 104-0045
- Rekruttering
- National Cancer Center Hospital - Tsukiji Campus
-
Shinjuku, Tokyo, Japan, 160-0023
- Rekruttering
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
- Rekruttering
- Yamaguchi University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Key Exclusion Criteria:
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Administered per the protocol |
|
Eksperimentell: REGN7508
|
Administered per the protocol
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Tid til første hendelse av sentralt vurdert International Society of Thrombosis and Hemostasis (ISTH) stor blødning eller klinisk relevant ikke-stor (CRNM) blødning
Tidsramme: Gjennom 6 måneder
|
Gjennom 6 måneder
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Tidsramme: Through 6 months
|
Through 6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forekomst av behandlingsrelaterte bivirkninger (TEAEs)
Tidsramme: Opp til dag 245
|
Opp til dag 245
|
|
Alvorlighetsgrad av TEAEs
Tidsramme: Opp til dag 245
|
Opp til dag 245
|
|
Størrelsen av ADA til REGN7508
Tidsramme: Opp til dag 245
|
Opp til dag 245
|
|
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic VTE
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic DVT
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic non-fatal PE
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of thromboembolism-related death
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental VTE
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE-related death
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Tidsramme: Through 6 months
|
Through 6 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Tidsramme: Up to day 245
|
Up to day 245
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- R7508-CAT-2392
- 2024-519298-21-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Tilgangskriterier for IPD-deling
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .